Table II.
Response to treatment.
| A, Response to first treatment | |||
|---|---|---|---|
| Arm A (n=49) | Arm B (n=48) | ||
| Type of response | Carboplatin+PTX | Gefitinib | |
| Assessable cases, n | 49 | 47 | |
| CR | 0 | 0 | |
| PR | 16 | 15 | |
| SD | 20 | 11 | |
| PD | 10 | 19 | |
| NE | 3 | 2 | |
| RR, % (95% CI) | 34.8 (21.0–48.5) | 33.3 (19.6–47.1) | |
| B, Response to second treatment | |||
| Type of response | Gefitinib | Carboplatin+PTX | |
| Assessable cases, n | 29 | 35 | |
| CR | 0 | 1 | |
| PR | 10 | 8 | |
| SD | 5 | 17 | |
| PD | 13 | 8 | |
| NE | 1 | 1 | |
| RR, % (95% CI) | 35.7 (18.0–53.5) | 26.5 (11.6–41.3) | |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; RR, response rate; PTX, paclitaxel; CI, confidence interval.